stockportfolio.pro
McKesson Corporation (MCK)
Healthcare · Medical Distribution · NYSE
McKesson Corporation revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $198.53B | $208.36B | $214.32B | $231.05B | $238.23B | $263.97B | $276.71B | $308.95B | $359.05B | $403.43B |
| Gross profit | $11.27B | $11.18B | $11.75B | $12.02B | $12.15B | $13.13B | $12.36B | $12.83B | $13.32B | $14.55B |
| Net income | $5.07B | $67.00M | $34.00M | $900.00M | $-4.54B | $1.11B | $3.56B | $3.00B | $3.29B | $4.76B |
| Net margin | 2.6% | 0.0% | 0.0% | 0.4% | -1.9% | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% |
Source: McKesson Corporation SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into MCK stock?
At today's market cap of $94.27B, McKesson Corporation is priced for free-cash-flow growth of about 5.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $5.72B from the FY ending 2026-03-31). For comparison, free cash flow actually grew 6.9%/yr over the last five fiscal years and revenue 11.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of McKesson Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MCK in your portfolio →
McKesson Corporation financial history by metric
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
McKesson Corporation — frequently asked questions
What is McKesson Corporation's revenue?
McKesson Corporation (MCK) reported revenue of $403.43B for fiscal year 2026, up 12.4% from the prior year, according to its SEC filings.
Is McKesson Corporation profitable?
Yes. MCK earned net income of $4.76B in fiscal 2026, a net margin of 1.2%.
What is MCK's P/E ratio?
McKesson Corporation trades at a price-to-earnings ratio of about 20.4 based on the latest data in our nightly-refreshed cache.
How fast is McKesson Corporation growing?
MCK's revenue grew at roughly 11.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does McKesson Corporation have?
As of fiscal year 2026, MCK carried roughly $6.53B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is McKesson Corporation's gross margin?
MCK's gross margin was 3.6% in fiscal 2026 — gross profit of $14.55B on revenue of $403.43B.
What is McKesson Corporation's market cap?
McKesson Corporation (MCK) has a market capitalization of about $94.27B, based on the latest data in our nightly-refreshed cache.
When does McKesson Corporation's fiscal year end?
MCK's fiscal year ends in March. Its most recent annual filing covers the fiscal year ending 2026-03-31.
What growth is priced into MCK stock?
At today's market cap of $94.27B, McKesson Corporation is priced for free-cash-flow growth of about 5.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $5.72B from the FY ending 2026-03-31). For comparison, free cash flow actually grew 6.9%/yr over the last five fiscal years and revenue 11.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from McKesson Corporation's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.